MLST8 (MTOR Associated Protein, LST8 Homolog) is a critical component of both mTORC1 and mTORC2 complexes and plays important roles in neurodegenerative diseases. This page provides comprehensive information about its structure, function, and therapeutic implications.
MLST8 is a conserved protein component of the mechanistic Target of Rapamycin (mTOR) kinase complexes. As a core subunit, MLST8 provides structural support and helps regulate the kinase activity of both mTORC1 and mTORC2. Targeting MLST8 and mTOR signaling has significant therapeutic potential in neurodegenerative diseases.
| Attribute |
Value |
| Protein Name |
MLST8 |
| Gene Symbol |
MLST8 |
| Full Name |
MTOR Associated Protein, LST8 Homolog |
| UniProt ID |
Q8BXR0 (Mouse), Q9BVA0 (Human) |
| Gene ID |
84916 (Human) |
| Molecular Weight |
~36 kDa |
| Subcellular Localization |
Lysosomal membrane, cytoplasm |
| Protein Family |
LST8/MLST8 family |
| Tissue Expression |
Ubiquitous; highest in brain, heart, skeletal muscle |
MLST8 contains several key structural features:
- WD40 Repeat Domains: Seven WD40 repeats form a beta-propeller structure that mediates protein-protein interactions
- Beta-Propeller Structure: Provides a stable scaffold for complex formation
- HEAT Repeats: Facilitate interactions with other mTOR complex components
- Phosphorylation Sites: Multiple serine/threonine phosphorylation sites regulate function
The structure allows MLST8 to serve as a scaffolding protein that stabilizes both mTORC1 and mTORC2 complexes.
MLST8 is essential for mTOR complex function and structure:
- Structural Stabilization: Maintains mTORC1 integrity
- Kinase Activity Enhancement: Amplifies mTOR catalytic activity
- Substrate Recruitment: Facilitates substrate access to the kinase domain
- RAPTOR Interaction: Works with RAPTOR to regulate mTORC1 signaling
- Complex Assembly: Required for proper mTORC2 formation
- Kinase Activation: Essential for mTORC2 autophosphorylation
- AKT Activation: Mediates AKT phosphorylation at Ser473
- RICTOR Interaction: Partners with RICTOR for mTORC2 function
MLST8 exhibits broad tissue expression with notable levels in the nervous system:
- Cerebral Cortex: High expression in pyramidal neurons
- Hippocampus: Particularly in CA1-CA3 regions
- Cerebellum: Purkinje cells show significant expression
- Basal Ganglia: Moderate expression in striatal neurons
- Synaptic Compartments: Presynaptic terminals and postsynaptic densities
- Dendrites and Axons: Cytosolic and membrane-associated pools
- Lysosomal Membrane: Critical for mTORC1 localization
- Cytoplasm: General cytoplasmic distribution
MLST8 and mTOR signaling are critically involved in Alzheimer's disease pathogenesis:
- mTORC1 Hyperactivation: Elevated mTORC1 activity in AD brains correlates with cognitive decline
- Autophagy Impairment: mTORC1 inhibits autophagy, leading to accumulated protein aggregates (amyloid-beta, tau)
- Synaptic Plasticity Deficits: mTOR dysregulation affects long-term potentiation (LTP)
- Memory Impairment: mTORC1 hyperactivation impairs memory consolidation
- Therapeutic Targeting: mTOR inhibitors show promise in preclinical AD models
Key References:
MLST8/mTOR signaling plays a complex role in PD:
- Alpha-Synuclein Metabolism: mTOR regulates autophagy of alpha-synuclein aggregates
- Mitochondrial Dysfunction: mTORC2/PI3K/AKT pathway affects mitochondrial health
- Dopaminergic Neuron Survival: mTOR activity influences neuronal viability
- LRRK2 Interaction: G2019S LRRK2 mutation affects mTOR signaling
Key References:
- mTORC1 Hyperactivation: TSC1/TSC2 mutations cause constitutive mTORC1 activation
- Neurological Manifestations: Seizures, intellectual disability, autism
- Rapamycin Treatment: mTOR inhibitors effectively reduce tumor growth and seizures
- mTOR Dysregulation: Observed in ALS patient tissues and models
- Autophagy Defects: Impaired clearance of mutant proteins (SOD1, FUS, TDP-43)
- Therapeutic Potential: mTOR modulation may benefit ALS patients
Amino Acids → Rag GTPases → mTORC1 (RAPTOR) → S6K1/4E-BP1
↓
Protein Synthesis, Autophagy
Growth Factors → PI3K → PDK1 → AKT → mTORC2 (RICTOR)
↓
AKT (Ser473), PKCα, SGK1
| Drug |
Type |
Clinical Use |
Notes |
| Rapamycin (Sirolimus) |
Allosteric |
Transplant, TSC |
Selectively inhibits mTORC1 |
| Everolimus |
Allosteric |
Cancer, TSC |
Rapamycin analog |
| Torin 1 |
ATP-competitive |
Research |
Inhibits both mTORC1/2 |
| AZD8055 |
ATP-competitive |
Clinical Trials |
Dual mTORC1/2 inhibitor |
- Trehalose: mTOR-independent autophagy inducer
- Resveratrol: SIRT1 activator, modulates mTOR
- Metformin: AMPK activator, indirectly reduces mTORC1
- Lithium: Autophagy enhancer via IMPase inhibition
- Combination Therapy: mTOR inhibitors with autophagy inducers
- Temporal Regulation: Intermittent dosing to avoid side effects
- Targeted Delivery: Nanoparticle-based brain delivery
- Biomarker Monitoring: Track p-S6 levels for response
- Mlst8 Constitutive Knockout: Viable with mild metabolic phenotypes
- Conditional Neuronal Knockout: Leads to impaired synaptic function
- Muscle-specific Knockout: Affects metabolism and function
- MLST8 Overexpression: Accelerates tumor growth
- mTORC1 Activation: Phenocopies TSC deficiency
MLST8 interacts with multiple proteins:
- mTOR: Kinase catalytic subunit
- RAPTOR: mTORC1-specific scaffolding protein
- RICTOR: mTORC2-specific scaffolding protein
- mLST8: Same protein (homodimerization)
- S6K1 (RPS6KB1): Phosphorylation target
- 4E-BP1 (EIF4EBP1): Translation repressor
- AKT (PKB): Phosphorylation by mTORC2
- PKCα: Phosphorylation target
- TSC1/TSC2: Rheb GTPase-activating complex
- Rag GTPases: Amino acid sensing
- PRAS40: mTORC1 inhibitor
- Phospho-S6 (Ser240/244): Readout of mTORC1 activity
- Phospho-AKT (Ser473): Readout of mTORC2 activity
- LC3-II: Autophagy flux marker
- Rapamycin for Alzheimer's disease (NCT04629443)
- Everolimus for TSC-associated seizures
- AZD8055 for solid tumors (completed)
- mTORC1/C2 Specific Targeting: Developing isoform-selective inhibitors
- Age-related mTOR Dysregulation: Understanding circadian regulation
- Blood-Brain Barrier Penetration: Improving drug delivery
- Personalized Medicine: Genetic stratification for treatment
- Optimal dosing regimens for neurodegenerative diseases
- Long-term safety of chronic mTOR inhibition
- Biomarkers for treatment response
- Combination therapy protocols
The discovery of MLST8 as an mTOR component followed the identification of mTOR itself:
- 1991: mTOR identified as the target of rapamycin
- 1994: mTORC1 and mTORC2 complexes characterized
- 2002: MLST8 identified as shared component
- 2007: Crystal structure of mTOR kinase domain solved
- 2010s: mTOR roles in neurodegeneration extensively studied
The study of Lamtor2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:12150926 - Discovery of mTORC1 structure
- PMID:25396082 - mTOR in Alzheimer's disease pathogenesis
- PMID:26255403 - Autophagy mechanisms in neurodegeneration
- PMID:26925799 - mTOR signaling in Parkinson's disease
- PMID:28749530 - Alpha-synuclein and autophagy
- PMID:22586121 - mTORC2 structure and function
- PMID:19339617 - WD40 repeat protein structures
- PMID:24464289 - mTOR inhibitors in neurological disorders
- PMID:25939662 - Rapamycin and longevity
- PMID:28615654 - Autophagy induction for neurodegeneration